John R. Ieni

Eisai, Inc., Andover, MA, United States 
"John Ieni"
Mean distance: 16.75 (cluster 7)
Cross-listing: Alzheimer's Tree

BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Nirogi R, Ieni J, Goyal VK, et al. (2022) Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study. Alzheimer's & Dementia (New York, N. Y.). 8: e12307
Doody RS, Corey-Bloom J, Zhang R, et al. (2008) Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease. Drugs & Aging. 25: 163-74
Feldman H, Gauthier S, Hecker J, et al. (2005) Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. International Journal of Geriatric Psychiatry. 20: 559-69
Krishnan KR, Charles HC, Doraiswamy PM, et al. (2003) Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. The American Journal of Psychiatry. 160: 2003-11
Geldmacher DS, Provenzano G, McRae T, et al. (2003) Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. Journal of the American Geriatrics Society. 51: 937-44
Tune L, Tiseo PJ, Ieni J, et al. (2003) Donepezil HCl (E2020) Maintains Functional Brain Activity in Patients With Alzheimer Disease: Results of a 24-Week, Double-Blind, Placebo-Controlled Study American Journal of Geriatric Psychiatry. 11: 169-177
Feldman H, Gauthier S, Hecker J, et al. (2003) P.4.040 Donepezil has significant functional and behavioral benefits in patients with severe Alzheimer's disease European Neuropsychopharmacology. 13
Wilkinson DG, Passmore AP, Bullock R, et al. (2002) A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. International Journal of Clinical Practice. 56: 441-6
Mohs RC, Doody RS, Morris JC, et al. (2001) A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 57: 481-8
Provenzano G, Duttagupta S, McRae T, et al. (2001) Ppn13: Delays In Nursing Home Placement For Patients With Alzheimer'S Disease Associated With Treatment With Donepezil May Have Health Care Cost-Saving Implications Value in Health. 4: 158
See more...